ProfileGDS5678 / 1432304_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 82% 80% 79% 77% 78% 83% 81% 78% 78% 79% 83% 80% 82% 80% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.9089682
GSM967853U87-EV human glioblastoma xenograft - Control 25.628280
GSM967854U87-EV human glioblastoma xenograft - Control 35.5257279
GSM967855U87-EV human glioblastoma xenograft - Control 45.4177277
GSM967856U87-EV human glioblastoma xenograft - Control 55.445578
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.8870683
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.6736281
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.4165978
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.3743678
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.4999679
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.122783
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.6413580
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.868382
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.5890280